ONVO vs. GENE, SRNE, COEP, BCDA, SNTI, IKT, CELZ, CHRO, TTNP, and FRTX
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Coeptis Therapeutics (COEP), BioCardia (BCDA), Senti Biosciences (SNTI), Inhibikase Therapeutics (IKT), Creative Medical Technology (CELZ), Chromocell Therapeutics (CHRO), Titan Pharmaceuticals (TTNP), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Organovo (NASDAQ:ONVO) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Genetic Technologies' return on equity of 0.00% beat Organovo's return on equity.
Genetic Technologies has higher revenue and earnings than Organovo.
Organovo received 35 more outperform votes than Genetic Technologies when rated by MarketBeat users. However, 55.33% of users gave Genetic Technologies an outperform vote while only 50.78% of users gave Organovo an outperform vote.
8.2% of Organovo shares are owned by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are owned by institutional investors. 5.0% of Organovo shares are owned by company insiders. Comparatively, 6.5% of Genetic Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Organovo has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
In the previous week, Genetic Technologies had 11 more articles in the media than Organovo. MarketBeat recorded 11 mentions for Genetic Technologies and 0 mentions for Organovo. Organovo's average media sentiment score of 0.36 beat Genetic Technologies' score of -0.18 indicating that Organovo is being referred to more favorably in the media.
Summary
Genetic Technologies beats Organovo on 8 of the 12 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
